If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnimalcare Grp Regulatory News (ANCR)

Share Price Information for Animalcare Grp (ANCR)

Share Price is delayed by 15 minutes
Get Live Data
333.50    0.00 (0.00%)
Bid:
332.00
Ask:
335.00
Spread: 3.00 (0.904%)
Market Cap: £230.27m
ANCR Live PriceLast checked at - London Stock Exchange

Intraday Animalcare Grp Share Chart

AGM Statement

28 Oct 2011 07:00

RNS Number : 0094R
Animalcare Group PLC
28 October 2011
 



Animalcare Group plc

("Animalcare")

 

AGM Statement

 

Animalcare Group plc (AIM: ANCR), a leading supplier of veterinary medicines, will hold its Annual General Meeting today at The Bridge Hotel, Walshford, Wetherby, North Yorkshire, LS22 5HS at 11.30am.

 

Ahead of the formal proceedings Animalcare will provide the following update to shareholders:

 

Trading in the first quarter has been satisfactory and continues to be in line with your Board's expectations.

 

As we mentioned at the time of our full year results we were aiming to launch two new products with a third complementary product in the first half of October. This has proceeded as planned and earlier this month we launched Torphasol, an analgesic for horses, and Detonervin, an equine sedative. Emdocam Equine, an anti-inflammatory for horses, will launch very soon. In addition to these products we also launched an antibiotic for cattle called Tilmodil in September.

 

In our results statement we flagged up that we also have a very important addition to our range finishing its regulatory passage. This has now been completed and with marketing authorisation received we expect to launch this produce in the near future and will provide an update at the appropriate time.

 

It has been our recent aim to launch four new generic veterinary medicines each year. This was achieved last year through the launch of Anivac VHD, Florgane, Sedastart and Sedastop and we are very pleased that we have launched four new products so early in our financial year with a fifth product looking to launch in the near future.

 

Finally, the Board has been very pleased with the underlying cash flow of the business and we announced in September that we are recommending a final dividend of 3p per share bringing to total dividend to 4p for the year, which, subject to shareholder approval later in the meeting, we propose to pay to shareholders on 7 November.

 

For further information:

 

Animalcare Group plc

Stephen Wildridge (Chief Executive Officer)

Tel: 01904 487 601

Brewin Dolphin (NOMAD)

Neil Baldwin

Tel: 0845 213 4726

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

paul.mcmanus@walbrookpr.com

Helen Westaway

helen.westaway@walbrookpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOAFELFWWFFSELS
Date   Source Headline
17th Apr 20264:37 pmRNSForm 8.3 - Animalcare Group plc
17th Apr 20263:44 pmGNWForm 8.3 - Animalcare Group plc - Octopus Investments
17th Apr 20263:44 pmBUSForm 8.3 - Animalcare Group plc - Octopus Investments
17th Apr 202612:29 pmRNSForm 8.3 - Animalcare Group plc
17th Apr 202612:21 pmRNSForm 8.3 - ANIMALCARE GROUP PLC
17th Apr 202612:00 pmRNSForm 8.5 (EPT/RI)
17th Apr 20269:09 amGNWForm 8.3 - [ANIMALCARE GROUP PLC - 16 04 2026] - (CGWL)
17th Apr 20269:09 amBUSForm 8.3 - [ANIMALCARE GROUP PLC - 16 04 2026] - (CGWL)
17th Apr 20269:07 amGNWForm 8.3 - [ANIMALCARE GROUP PLC - Opening Disclosure - 16 04 2026] - (CGAML)
17th Apr 20269:07 amBUSForm 8.3 - [ANIMALCARE GROUP PLC - Opening Disclosure - 16 04 2026] - (CGAML)
16th Apr 20262:53 pmGNWForm 8.3 - Animalcare Group plc - Octopus Investments
16th Apr 20262:53 pmBUSForm 8.3 - Animalcare Group plc - Octopus Investments
16th Apr 20262:00 pmRNSForm 8.3 - Animalcare Group Plc
16th Apr 20269:57 amPRNForm 8.3 - Animalcare Group Plc
16th Apr 20267:45 amRNSDisclosure Table
16th Apr 20267:00 amRNSRecommended Acquisition of Animalcare Group plc
4th Mar 20267:00 amRNSCapital Markets Event: In Good Health
22nd Jan 202612:54 pmRNSNotification of major holdings
22nd Jan 20267:00 amRNSTrading Update & Notice of Capital Markets Event
5th Jan 20262:34 pmRNSNotification of Major Holding in Company
23rd Dec 20257:00 amRNSGrant of options and PDMR Dealing
23rd Dec 20257:00 amRNSGrant of options and PDMR Dealing
22nd Dec 20253:39 pmRNSNotification of Major Holding in Company
22nd Dec 20253:39 pmRNSNotification of Major Holding in Company
22nd Dec 20257:00 amRNSNotification of Major Holding in Company
22nd Dec 20257:00 amRNSNotification of Major Holding in Company
19th Nov 202510:57 amRNSPDMR Dealing
19th Nov 20257:45 amRNSExercise of Options and Total Voting Rights
19th Nov 20257:00 amRNSNotification of Major Holding in Company
7th Nov 202511:57 amRNSNotification of Major Holding in Company
22nd Oct 20257:00 amRNSNotification of Major Holding in Company
21st Oct 202512:01 pmRNSNotification of Major Holding in Company
30th Sep 20257:00 amRNSInterim Results for six months ended 30 June 2025
24th Sep 20257:00 amRNSCollaboration to develop treatment for sweet itch
23rd Sep 20257:00 amRNSNotice of Results & Presentations
22nd Aug 20257:00 amRNS-RAcquisition of VHH NGF programme & related assets
24th Jul 20257:00 amRNSH1 Trading Update and Notice of Results
13th Jun 20257:42 amRNSStrategic investment in Australian business
10th Jun 20254:36 pmRNSResult of 2025 AGM
30th May 20257:00 amRNSExercise of Options and Total Voting Rights
23rd May 20259:21 amRNSNotification of Major Holding in Company
16th May 20257:00 amRNS2024 Annual Report and Notice of 2025 AGM
29th Apr 20252:06 pmRNSFinal Dividend Timetable
29th Apr 20257:00 amRNSPreliminary Full Year Results
22nd Apr 20251:23 pmRNSNotification of Major Holding in Company
16th Apr 20257:00 amRNSNotice of Results and Presentations
23rd Jan 20257:00 amRNS2024 Full Year Trading Update
20th Jan 20257:00 amRNSExercise of Options and Total Voting Rights
3rd Jan 202510:12 amRNSCompletion of Randlab acquisition
2nd Jan 202510:11 amRNSNotification of Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.